Resmetirom for adults with fatty liver disease causing liver inflammation (MASH)
Tests resmetirom in Pakistani adults with MASH confirmed by a liver scan.
Plain-language title generated from the registry record
Registry title: Resmiterom Efficacy & Safety in Patients With MASH
Key facts
- Where
- Rawalpindi, PakistanSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07249788, who can take part
Where in Pakistan
- Liver transplant center, Holy family hospitalRawalpindi, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nabiqasim Industries (Pvt) Ltd
- Trial code
- NCT07249788
- Record updated
- 3 December 2025
- Original description
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.Read full original descriptionShow less
Clinical Evaluation of Safety and Efficacy of Resmiterom in Patients With MASH (Metabolic Dysfunction-Associated Steato-Hepatitis) A Prospective, Open-label, Interventional Study
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
Inclusion: • At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension); Clinical diagnosis of MASH using:; LSM ≥ 8.5kpa And/or; FAST score ≥0.67 And/or; FibroScan CAP ≥ 275 dB/m And/or; FIB-4 > 1.3.
Exclusion: • History of drug addiction and alcoholism; Cirrhosis or decompensated liver disease; Chronic viral hepatitis HBV, HCV); MACE including MI, Stroke, PE etc; Pregnant/lactating women; Concurrent use of other investigational drugs; History of other liver diseases (viral, autoimmune, drug-induced, alcohol); Previous use of resmetirom in last 6 months; Significant renal impairment (eGFR <30).